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Monogenic diseases are ideal candidates for treatment by the emerging advanced therapies, which are capable of
correcting alterations in protein expression that result from genetic mutation. In hemophilia A and B such
alterations affect the activity of coagulation factors VIII and IX, respectively, and are responsible for the development
of the disease. Advanced therapies may involve the replacement of a deficient gene by a healthy gene so that it
generates a certain functional, structural or transport protein (gene therapy); the incorporation of a full array of
healthy genes and proteins through perfusion or transplantation of healthy cells (cell therapy); or tissue
transplantation and formation of healthy organs (tissue engineering). For their part, induced pluripotent stem cells
have recently been shown to also play a significant role in the fields of cell therapy and tissue engineering.
Hemophilia is optimally suited for advanced therapies owing to the fact that, as a monogenic condition, it does not
require very high expression levels of a coagulation factor to reach moderate disease status. As a result, significant
progress has been possible with respect to these kinds of strategies, especially in the fields of gene therapy (by
using viral and non-viral vectors) and cell therapy (by means of several types of target cells). Thus, although still
considered a rare disorder, hemophilia is now recognized as a condition amenable to gene therapy, which can be
administered in the form of lentiviral and adeno-associated vectors applied to adult stem cells, autologous
fibroblasts, platelets and hematopoietic stem cells; by means of non-viral vectors; or through the repair of
mutations by chimeric oligonucleotides. In hemophilia, cell therapy approaches have been based mainly on
transplantation of healthy cells (adult stem cells or induced pluripotent cell-derived progenitor cells) in order to
restore alterations in coagulation factor expression.
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Hemophilia is a recessive X-linked hereditary disorder
caused by a deficiency of coagulation factor VIII
(hemophilia A) or IX (hemophilia B). The disease is con-
sidered to be severe when factor levels are below 1% of
normal values, moderate when they are between 1 and
5% and mild when levels range between 5% and 40% [1].
As the prevalence of the disease is 7.7/100,000, it is con-
sidered a rare hematologic disorder (Orpha number
ORPHA448) (Table 1).
As other medical conditions, hemophilia is a chronic
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reproduction in any medium, provided the orpharmaceutical costs which, in less advantaged coun-
tries, could result in disabling clinical conditions if not
in a higher mortality rate. Contrary to other rare dis-
eases, over the last few decades hemophilia has benefited
from a greater understanding of the causes and mechan-
isms responsible for its development as well as of the
molecular and physiological characteristics of the disease
and its proper diagnostic and clinical management
(Table 2). This has undoubtedly aided in the design of
highly appropriate treatment schedules [1].
The etiopathogenesis of the disease is related to differ-
ent kinds of mutations (large deletions and insertions,
inversions and point mutations) that occur in the gene
expressing the deficient coagulation factor. The clinical
characteristics of both types of hemophilia are very simi-
lar: spontaneous or traumatic hemorrhages, muscle
hematomas, hemophilic arthropathy resulting from thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Classification (Orpha number), synonyms, prevalence and clinical description of hemophilia (Adapted from
Orphanet portal [http://www.orpha.net])
Type of hemophilia Orpha
number
Synonyms Prevalence Clinical description
Hemophilia (general) 448 Factor VIII or IX
deficiency
7.7/100,000 Bleeding episodes.
Hemophilia A 98878 Factor VIII
deficiency
1/6,000 Spontaneous or prolonged hemorrhages.
Hemophilia B 98879 Factor IX
deficiency
1/30,000 Spontaneous or prolonged hemorrhages.
Mild hemophilia A 169808 Mild factor VIII
deficiency
40% of all cases
of hemophilia
A
Small deficiency of factor VIII leading to abnormal bleeding as a result of
minor injuries, or following surgery or tooth extraction. The biological
activity of factor VIII is between 5 and 40%. Spontaneous hemorrhages
do not occur.
Mild hemophilia B 169799 Mild factor IX
deficiency
30% of all cases
of hemophilia B
Small deficiency of factor IX leading to abnormal bleeding as a result of
minor injuries, or following surgery or tooth extraction. The biological
activity of factor IX is between 5 and 40%. Spontaneous hemorrhages do
not occur.
Moderately severe
hemophilia A
169805 Moderately severe
factor VIII
deficiency
20% of all cases
of hemophilia
A
Abnormal bleeding as a result of minor injuries, or following surgery or
tooth extraction. The biological activity of factor VIII is between 1% and
5%. Spontaneous hemorrhages are rare.
Moderately severe
hemophilia B
169796 Moderately severe
factor IX deficiency
30% of all cases
of hemophilia B
Abnormal bleeding as a result of minor injuries, or following surgery or
tooth extraction. The biological activity of factor IX is between 1% and
5%. Spontaneous hemorrhages are rare.
Severe hemophilia A 169802 Severe factor VIII
deficiency
40% of all cases
of hemophilia
A
Frequent spontaneous hemorrhage and abnormal bleeding as a result of
minor injuries, or following surgery or tooth extraction. The biological
activity of factor VIII is below 1%.
Severe hemophilia B 169793 Severe factor IX
deficiency
40% of all cases
of hemophilia B
Frequent spontaneous hemorrhage and abnormal bleeding as a result of
minor injuries, or following surgery or tooth extraction. The biological
activity of factor IX is below 1%.
Symptomatic form of
hemophilia A in female
carriers
177926 Hemophilia A
carriers
Unknown(very
rare)
In some women with mutations in the F8 gene, encoding coagulation
factor VIII. Symptoms include abnormal bleeding as a result of minor
injuries, or following surgery or tooth extraction. Spontaneous
hemorrhages may occur occasionally. The biological activity of factor VIII
is below ~30%.
Symptomatic form of
hemophilia B in female
carriers
177929 Hemophilia B
carriers
Unknown (very
rare)
In some women with mutations in the F9 gene, encoding coagulation
factor IX. Symptoms include abnormal bleeding as a result of minor
injuries, or following surgery or tooth extraction. Spontaneous
hemorrhages may occur occasionally. The biological activity of factor IX
is below ~30%.
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the target joints, or hemorrhages in the central nervous
system (Table 1). In the absence of appropriate replace-
ment treatment with exogenous coagulation factors, these
manifestations of the disease can have disabling or evenTable 2 Some molecular and physiological characteristics of h
Type of
hemophilia
Deficient
factor
Protein size
(Kilodaltons)
DNA
length
(bp)
Half life
(Hours)
Fun
co
c
Hemophilia A VIII 280 7056 8-12 Activate
and ac
Hemophilia B IX 68 1389 15-25 Activa
and a
1Normal plasma level of coagulation factors: Factor VIII, 200 ng/mL; factor IX, 5000 n
increases the activity of factor in plasma, 1% to 2% of normal level; 3FX, factor X; 4Ffatal consequences thus negatively impacting patients'
quality of life and reducing their life expectancy [2].
Bleeding episodes may be spontaneous in the severe and
(less so) in the moderate forms of the disease, with 70%
of them being articular, 15% muscular and 15% visceral.emophilia A and B
ction in the
agulation
ascade
Plasma concentration (ng/ml)1,2
Mild hemophilia Moderately Severe
Hemophilia
Severe
Hemophilia
d by thrombin
tivates to FX3
10-80 (5-40%) 2-10 (1-5%) < 2 (<1%)
ted by FXIa4,
ctivates to FX
500-2000 (5-40%) 50-500 (1-5%) < 50 (<1%)
g/mL; 2One International Unit (IU) of factor VIII or IX, per kg of body weight,
XIa, factor XI activated.
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hemophilia and degree of involvement as well as detect-
ing symptomatic or asymptomatic carriers of the disease,
either obligate (daughters of hemophiliacs) or de novo
(women by sporadic and spontaneous mutations). Diag-
nostic methods are based on the determination of co-
agulation factor levels in plasma and the detection of the
mutation in the DNA extracted from peripheral blood
leucocytes by means of direct or indirect genetic meth-
ods (detection of genetic polymorphism).
As hemophilia is a gender-related condition, genetic
guidance is provided to couples on the basis of an odds
analysis based on genealogy and coagulation factor data
and a study of the mutation responsible for the disease.
Moreover, either a prenatal diagnosis [3], —which can
now be carried out non-invasively [4]—, or a pre-
implantational diagnosis are provided [5]. In this respect,
it is necessary to emphasize that access to prenatal or
pre-implantation genetic diagnosis is not universally
available but rather depends on the economic con-
straints imposed by different countries in accordance
with their development status.
At present, patients with hemophilia benefit from opti-
mized treatment schedules based on the intravenous sys-
temic delivery of exogenous coagulation factors, either
prophylactically or on demand protocols. The current
policy in developed countries is in general to administer
a prophylactic treatment (2 or 3 times a week) from
early childhood into adulthood [2]. Such prophylactic
protocols result in a marked improvement in patients'
quality of life on account of the prevention of
hemophilic arthropathy and other fatal manifestations of
the disease as well as a reduction in the long-term costs
of treatment because of a decrease in the need of surgi-
cal procedures such as arthrodesis, arthroplasty or syno-
vectomy [6].
Conventional treatment of hemophilia [7,8] is cur-
rently based on the use of plasma-derived products —
duly treated with heat and detergent to inactivate lipid-
coated viruses [9]—, or the recently developed recom-
binant high-purity coagulation factor concentrates which
do not contain proteins of human or animal origin
[10,11]. Both kinds of factor boast high efficacy and
safety profiles, at least for the inactivation-susceptible
pathogens known to date. The choice of one product
over the other is usually based on the clinical character-
istics of the patient and on cost and availability consid-
erations [12,13].
Now that infections by pathogenic viruses (VIH,
HCV) that were common a few decades ago have been
eradicated, the most distressing adverse effect observed
when using both recombinant and plasma-derived pro-
ducts is the development of antibodies (inhibitors)
against the perfused exogenous factors [14,15]. Theappearance of inhibitors renders current treatment with
factor concentrates inefficient, increasing morbidity and
mortality, leading to the early onset of hemophilic
arthropathy and disability and to a consequent reduction
in patients' quality of life. Inhibitors also result in higher
costs as treatment must be provided both for bleeding
episodes and inhibitor eradication (immune tolerance
induction). The incidence of inhibitors is around 30%
in hemophilia A and 6% in hemophilia B [2].
The immunologic mechanism whereby these neu-
tralizing antibodies are generated is highly complex
and involves several messenger molecules (tumor ne-
crosis factor, interleukins. . .), and cells (T-lymphocytes
B-lymphocytes, macrophages . . .). They are directed at
certain regions in the factor molecule that interact with
other components of the coagulation cascade and, de-
pending on their titre level and on whether they are
transient or persistent, they will bring about greater or
lesser alterations in the coagulation cascade. The causes
that influence inhibitor development may be genetic —
inherent in the patients themselves [14]—, such as ethni-
city, familial history, type of mutation or certain changes
in some of the genes involved in the immune response;
or non-genetic —environmental [16]—, such as stimula-
tion of the immune system by other antigens or the treat-
ment regimen used (prophylactic vs. on demand). The
influence of type of factor concentrate used (plasma-
derived or recombinant) is still a subject for debated
[17,18].
Short and medium-term perspectives for the treatment
of hemophilia strongly rely on the current research
efforts directed increasing the safety levels of (especially)
plasma-derived factors with respect to the detection and
subsequent inactivation of blood-borne pathogens in
donors, such as prions and other potential emerging
agents [19-21]. It is also important to enhance the effi-
ciency of recombinant factors increasing their half-life
(by PEGylating the factor molecule or using fusion pro-
teins, both for factor VIII and factor IX [22-25]). These
studies are now in progress and no definite statements
can be made about the safety of long-acting products as
none of them have yet been authorized for clinical use.
Another strategy could be to attenuate their immuno-
genic capacity to produce inhibitors by chemically modi-
fying them [26] or by developing recombinant factors of
human origin [27].
In the long term, efforts must be directed at the devel-
opment of advanced therapies, particularly strategies in
the field of gene therapy (by using adeno-associated viral
vectors) and cell therapy (by using adult stem cells or
induced pluripotent stem cells). The chief goal of these
new strategies will be to address some of the limitations
associated with current treatment options such as the
short in vivo half-life of administered factors, the risk of
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inhibitors. Another goal of the advanced therapies (cell
therapy) will be palliative treatment of the articular con-
sequences derived from hemophilic arthropathy [6].
Advanced therapies for the treatment of
hemophilia
In the future, the different types of advanced therapies
such as gene therapy, cell therapy and tissue engineer-
ing, as well as the more recently developed induced
pluripotent stem cells (iPSC) technology, may offer
innumerable clinical applications for the treatment of
certain monogenic diseases including hemophilia.
True as it is that hemophilia is well suited to be trea-
ted by advanced therapy protocols on account of its
monogenic nature and of the fact that a modest increase
in coagulation factor levels is enough to convert a severe
into a moderate phenotype, it cannot be forgotten that
research in this field is still at an early stage and substan-
tial efforts will have to be made before such therapies
can be made readily available to the patients, particularly
in terms of safety. Safety considerations will have to be
taken very seriously, notably in this group of patients
who present with specific clinical characteristics that
more often than not are the result of their past and
present-day treatment. These characteristics include the
presence of inhibitors or the predisposition to develop
them, the specific immunological status of these patients
and the presence of viral co-infections (HIV/HCV) [28].Table 3 Preclinical studies and clinical trials on gene- and cel
Authors [Reference] Vector or target (tissue) cells
Gene therapy (Preclinical studies)
Jeon et al. Ref.[35] LVV
Brown et al. Ref.[34] LVV
Ramezani et al. Ref.[36] LVV
Matsui. Ref.[37] LVV
Montgomery and Shi. Ref.[40] LVV
Gene therapy (Clinical trials)
Nathwani et al. Ref.[38] AAV (Immunosuppressive therap
Buchlis et al. Ref.[39] AAV
Cell therapy (Preclinical studies)
Aronovich et al. Ref.[43] Embryonic day 42 spleen tissue
Follenzi et al. Ref.[44] Liver sinusoidal endothelial cell
Follenzi et al. Ref.[45] Kupffer cells. Bone marrow-derived mesench
cells
Xu et al. Ref. [46] iPSCs from tail-tip fibroblasts and their differ
endothelial cells and their precurs
Yudav et al. Ref. [47] Transdifferentiation of iPSC-derived endothe
cells into hepatocytes
LVV, lentiviral vector; AAV, adeno-associated vector; FIX, factor IX.For these reasons, although optimism is certainly in
order, caution is of the essence to avoid raising false
expectations in both physicians and patients alike.
Gene therapy strategies
Gene therapy consists of transplantation of genetically
modified cells so that they may produce a functional
protein, and cell therapy in the transplantation of living
cells into an organism in order to repair tissue or restore
a deficient function. Both strategies are based on the use
of stem cells given their indefinite capacity to renew
themselves and differentiate to become cells of several
specific cell lines. All these are necessary conditions for
their clinical application [29].
The most significant breakthroughs in the field of
advanced therapies and hemophilia are chiefly related to
both preclinical and clinical trials in the fields of gene
therapy (through the use of viral and non-viral vectors)
and cell therapy (using several types of target cell)
(Table 3). Thus hemophilia reveals itself as a disease that
is highly amenable to be treated by gene therapy [30-33]
by means of lentiviral and adeno-associated vectors used
in adult stem cells and autologous fibroblasts, platelets
or hematopoietic stem cells; and of the transfer of non-
viral vectors and repair of mutations by chimeric oligo-
nucleotides. The studies published so far have, in the
most part, not reported any adverse event resulting from
the application of such strategies in the clinical trials
performed in terms of an immune-mediated transgenel therapy for hemophilia
Coagulation
factor expressed
Expression level (%)
VIII 1-5
IX 10
VIII <40
VIII <40
VIII <40
y) IX 2-11
IX FIX RNA expression and AAV DNA
persistence (<1% FIX)
VIII 30-40
s VIII 14-25
ymal stromal VIII 10-15
entiation into
ors
VIII 8-12
lial progenitor VIII 20
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such as innate cellular T cell toxicity to adeno-associated
capsid protein and the low efficacy obtained by non-viral
vectors are impeding and limiting their success [34].
Brown et al. [35] were the first to use lentiviral vectors
for treatment of hemophilia B. Using a lentiviral vector
containing a target sequence for the hematopoietic-
specific microRNA, miR-142-3p, they obtained 10% fac-
tor IX activity with no anti-FIX antibodies in hemophilia
B mice at over 280 days after injection. Since those
results were published, use of lentiviral vectors has not
ceased to grow. Thus, Jeon et al. [36] transduced this
type of viral vector into skeletal muscle to increase fac-
tor VIII expression. Factor VIII plasma levels at one
week post-injection were 5.19 ng/mL vs 0.21 ng/mL in
control rats, with those levels staying constant over 4
weeks with a single dose of the vector. More recently,
and also using lentiviral vectors, Ramezani et al. [37],
adapted a nonmyeloablative conditioning regimen and
directed factor VIII protein synthesis to B lineage cells
using an insulated lentiviral vector containing an im-
munoglobulin heavy chain enhancer-promoter. Trans-
plantation of lentiviral vector-modified hematopoietic
stem cell resulted in an increase in factor VIII plasma
levels for 6 months, with a low immune response against
the protein expressed and a correction of the hemophilic
phenotype in the transplanted mice.
Very recently, Matsui et al. [38], established a gene
therapy strategy using autologous circulating endothelial
progenitor cells transfected with lentiviral vectors con-
taining a canine FVIII transgene. When implanted sub-
cutaneously in a soluble basement membrane scaffold,
these cells produced a long-term FVIII expression over
6 months, and resulted in effective prophylaxis against
bleeding.
Ward et al. [39], have directly compared, using lentiviral
vectors, FVIII expression from FVIII-constructs contain-
ing various B domains from non–codon-optimized and
codon-optimized cDNA sequences without the con-
founding effect of variable immune responses against
human FVIII, neo epitopes and the Fugu B domain. A
dramatic increase in the observed level of secreted FVIII
from codon optimized cDNA sequences was obtained.
These results are in contrast to transient FVIII ex-
pression levels obtained from another many previous
approaches.
Gene therapy studies conducted in hemophilic patients
showed that use of adeno-associated vectors currently
constitutes the most promising option given the high
safety profile of such vectors, although they are not ex-
empt from immune response-related problems. Efforts
are nowadays directed at reducing the incidence of im-
mune rejection and increasing the efficacy and length of
expression. Several studies have been published in anattempt to optimize the use of viral vectors. Thus,
Nathwani et al. [40], completed a pioneering clinical trial
in patients with severe hemophilia B (<1% FIX). Patients
were perfused with a dose of a serotype-8-pseudotyped,
self-complementary adeno-associated vector that
expressed factor IX and could efficiently transduce hepa-
tocytes. Their results showed that factor IX expression
ranged between 2 and 11% of normal values. Significant
as they may seem, these results must be considered with
caution as the expression levels achieved rather than
normalize the patient's phenotype convert it to a mild-
to-moderate form. Also treatment with glucocorticoids
may be necessary to prevent immune rejection and in-
crease the duration of transgene expression. Due ac-
count must also be taken of the fact that the adeno-
associated vector has the potential to induce hepatotox-
icity. For all these reasons, these undoubtedly encour-
aging results can only be considered a first step in the
development of safe and effective advanced therapies for
the treatment of hemophilia.
A recent study [41] reported on the persistent long-
term expression of factor IX in parenteral administration
of an adeno-associated viral vector in muscle tissue. The
authors show that adeno-associated serotype-2-mediated
gene transfer to human skeletal muscle persists and is
transcriptionally and translationally active for a period of
up to 10 years. This is the longest reported transgene ex-
pression to date.
A new alternative that has been proposed in connec-
tion with gene therapy strategies for hemophilia is the
use of platelet targeting as a mechanism of drug delivery
[42]. Such a strategy could play an efficient clinical role
in the treatment of hemophilia and other hemostatic dis-
orders given that it would allow local release of factor
VIII and IX at the site of the bleeding-induced damage
and, at the same time, protect such factors from the ef-
fect of the inhibitors potentially present in plasma.
Non-viral strategies also play an important role in this
area as they constitute a safe alternative for the future in
the face of the limitations that have so far been asso-
ciated with viral vectors in terms of their biosafety and
potential clinical application.
Thus, Sivalingam et al. [43], evaluated the genotoxic
potential of phiC31 bacteriophage integrase-mediated
transgene integration in cord-lining epithelial cells cul-
tured from the human umbilical cord. This non-viral
strategy has made it possible to obtain stable factor VIII
secretion in vitro. Xenoimplantation of these protein-
secreting cell lines into immunocompetent hemophilic
mice corrects the severe form of the disease.
Our laboratory has advanced the use of nucleofection
as a non-viral transfection method to obtain factor IX
expression and secretion in adult adipose tissue-derived
mesenchymal stem cells [44]. Although it is certainly
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cols is lower than when viral vectors are used, it must be
remembered that achieving a factor plasma level of at
least 5% can transform a severe into a mild phenotype.
In addition, non-viral vectors provide higher safety levels
than viral ones.
Cell therapy strategies
The use of cell therapy in the treatment of hemophilia
has to date consisted mainly in the transplantation of
healthy cells in an attempt to repair or replace a coagu-
lation factor deficiency. These procedures have been
conducted mainly with adult stem cells and, more re-
cently, with progenitor cells partially differentiated from
iPSCs, albeit in most cases the mechanisms by which
transplanted cells (to a greater or lesser extent) engraft
and go on to proliferate and function remain unknown.
Aronovich et al. [45], have shown that transplantation
of embryonic day 42 spleen tissue in immunocompetent
mice with hemophilia A attenuates the severity of the
disease in the 2–3 months after the procedure. These
results would seem to indicate that transplantation of a
fetal spleen —obtained from a developmental stage prior
to the appearance of T-cells— may potentially be used
to treat some genetic disorders. For their part, Follenzi
et al. [46], reported that once liver sinusoidal endothelial
cells were transplanted and successfully engrafted into
mice with hemophilia A, they were seen to proliferate
and partially replace some areas of the hepatic endothe-
lium. This resulted in a restoration of factor VIII plasma
levels and in the correction of the bleeding phenotype.
More recently, this same team [47] demonstrated that
transplantation of healthy mouse Kupffer cells (liver
macrophage/mononuclear cells), which predominantly
originate from bone marrow, or of healthy bone
marrow-derived mesenchymal stromal cells, can correct
the phenotype of hemophilic mice and restore factor
VIII levels in plasma.
As far as the use of iPSCs is concerned, the first paper
was published by Xu et al. [48] who reported on the
generation of murine iPSCs from tail-tip fibroblasts and
their differentiation into endothelial cells and their pre-
cursors. These iPSC-derived cells express specific mem-
brane markers such as CD31, CD34 and Flk1, as well as
factor VIII. Following transplantation of these cells into
mice with hemophilia A, the latter survived the tail-clip
bleeding assay by over 3 months and their factor VIII
plasma levels increased to 8%-12%. Yadav et al. [49],
have studied the transdifferentiation of iPSC-derived
endothelial progenitor cells into hepatocytes (primary
cells of FVIII synthesis). These cells were injected into
the liver parenchyma where they integrated functionally
and made correction of the possible hemophilic pheno-
type. High levels of FVIII mRNA were detected in thespleen, heart, and kidney tissues of injected animals with
no induction of tumors or any other adverse events in
the long-term. Alipio et al. [50] for their part also
reported on the generation of factor VIII in a hemophilic
murine model one year after transplantation of iPSC-
derived endothelial cells.
Advanced therapies in the hemophilic arthropathy
Lastly, it is important to consider the potential applica-
tion of advanced therapies in the palliative treatment of
the articular consequences of hemophilic arthropathy.
Although adequate treatment is currently available for
hemophilia, which is specifically efficient regarding the
negative consequences of hemophilic arthropathy, it
cannot be forgotten that only 25% of hemophiliacs, most
of them living in developed countries, can benefit from
such treatment. In the rest of the world, hemophilic
arthropathy and its disabling sequelae are the norm. But
even in the developed world many patients still present
moderate or severe hemophilic arthropathy on account
of the fact that they either developed inhibitors or
started being treated a few decades ago when present-
day therapies were still unavailable.
Against this background, advanced therapies may con-
stitute a solution of these patients [6]. Chondrocyte im-
plantation and cell therapy using bioreactors, growth
factors, mesenchymal stem cells and genetically modified
cells may be used as an adjunct or even as an alternative
to the current approaches (bone marrow stimulation,
osteochondral autograft or allograft transplantation) for
the repair of chondral damage in advanced arthropathic
disease.
Mesenchymal stem cells appear hold great promise for
chondral repair given their high differentiation ability
and their proven therapeutic effects [51]. Implantation
of autologous chondrocytes or mesenchymal stem cells
was up to now able to address only highly localized
chondral lesions, and the use of bioreactors and growth
factors, which stimulate cartilage formation, may
optimize such strategies.
Concluding remarks
Hemophilia is highly amenable to treatment by protocols
based on advanced therapies ―gene therapy, cell ther-
apy, tissue engineering or induced pluripotent stem cell
technology—. This is because it is a monogenic disease
which requires low circulating levels of coagulation fac-
tor and no gene regulation to achieve a moderate pheno-
type, and because a large variety of pathological animal
models are available for experimentation. However,
advanced therapies are still at an early research phase
and much effort and investment will be required before
they can be applied in a generalized way. For these rea-
sons, although optimism is warranted care must be
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patients.
Safety is a key component in any therapeutic strategy
or pharmacological product. But for patients with
hemophilia safety is even more essential for several rea-
sons including the specific clinical characteristics of the
patients, such as the presence of inhibitors or the predis-
position to develop them; the alteration of the indivi-
dual's immunological status; or the presence of viral co-
infection with HIV/HCV.
The most significant advances made in the field of
advanced therapies and their application in the future
treatment of several diseases, and hemophilia in particu-
lar, have been related to the development of viral gene
therapy using lentiviral and adeno-associated vectors;
non-viral gene transfer by nucleofection, phiC31 bac-
teriophage integrase or lipofection; or mutation repair
by chimeric oligonucleotides. Cell therapy using adult,
fetal, embryonic or IPSC-derived stem cells has also
played a substantial role. Results were generally satisfac-
tory although the plasma levels of factor VIII or IX
obtained were, at best, those corresponding to a mild-
moderate phenotype of the disease when viral gene
transfer was employed and to a moderate phenotype
when non-viral methods were used. Even if duration of
expression of the protein was in some cases consider-
able, the factor plasma concentrations achieved were
nonetheless transient and eventually cleared. Moreover,
in the clinical trials carried out, hepatotoxic effects were
observed as a result of the use adeno-associated vectors
and of an immune response against the transgenes or
the components of the virus coating themselves. Factors
such as the need to use concomitant treatment with
immunosuppresors to overcome some of this problems,
as well as small sample sizes of patients and the difficul-
ties inherent in extrapolation of pre-clinical results to
humans and large-scale production of both vectors and
cells, have so far somewhat undermined the success
expected from these therapies.
Cell therapy approaches hold significant hope for pal-
liative treatment of the disabling articular sequelae of
hemophilic arthropathy in patients who, several decades
ago, had no access to the optimal treatment available at
present; in those that have developed inhibitors; or in
that 75% of patients on the planet for whom access to
adequate treatment is simply not possible.
An important consideration to be borne in mind when
implementing new therapeutic strategies is the feasibility
of the investment required. Given their low prevalence,
treatment of many rare diseases is unfortunately not
considered feasible in this respect. Feasibility of the in-
vestment must be considered in terms of justifying the
long-term benefits achieved both for a certain patient
population and for the entity laying out the funds. Thedetermining factors are the number of affected indivi-
duals, the costs derived from the current treatment of
these rare conditions, their chronicity and the long-term
duration and their consequences (emerging pathogen-
derived infections among others). The availability or
otherwise of conventional treatment together with other
disease-specific factors should also be taken into
account.
For the reasons above, hemophilia is an excellent and
financially feasible candidate for advanced therapies, if
for no other reason than the high cost of its current
treatment. When all of these factors are added to the
fact that hemophilia is a rare low-incidence disease and
to the technical and methodological problems men-
tioned above, it is not difficult to understand that pro-
gress will be slow. Even so, given that patient safety
should always be a paramount consideration, it may be
necessary to settle for slightly lower expression levels (a
mild-to-moderate phenotype) in return for higher safety
levels. The question is: how is this to be achieved? And,
though the answer is by no means an easy one, the
results obtained so far by the combination of cell therapy
and gene therapy —based on viral (lentiviral and adeno-
associated) vectors with improved transfection efficacy
and immunogenic properties, or non-viral vectors— may
be pointing in the right (and most promising) direction.
Finally, although optimism is clearly justified, fantasy
is best avoided in order not to raise false expectations in
the patients suffering from these rare diseases that may
be subject to either curative or palliative treatment by
advanced therapies protocols.
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